New guidance addresses Australian firms' worries over post-market reviews
This article was originally published in Scrip
Executive Summary
A new version of the Australian framework for post-market reviews, which are used to monitor marketed medicines in order to improve the quality of their use and help ensure the sustainability of the Pharmaceutical Benefits Scheme, is expected to be published soon following its adoption by the government and the pharmaceutical industry.